Inflammaging is real and measurable. Whether lowering it extends healthy life is unproven.

"Inflammaging," the slow rise in low-grade inflammation that comes with age, is a real and measurable phenomenon, linked to frailty, multiple diseases at once, and death, and researchers have now built a blood "clock" that quantifies it [s1][s2]. What remains unproven is the step that supplement sellers and longevity clinics skip to: that deliberately lowering this inflammation makes people live longer or healthier [s3].

What inflammaging is

The term describes a specific idea, not just "inflammation is bad." As people age, the immune system settles into a chronic, low-grade, sterile inflammatory state, meaning it is switched on without an infection to fight, and this smouldering activation is thought to contribute to the diseases of later life, from atherosclerosis to neurodegeneration [s1]. The influential 2018 framing calls this an immune-metabolic problem: the same ageing processes that drive metabolic decline also keep the immune system chronically primed [s1]. Chronic inflammation is one of the recognised hallmarks of ageing, the interlocking biological processes researchers use to describe how bodies grow old.

Crucially, inflammaging is not the acute inflammation of a sprained ankle or a sore throat, which is protective and resolves. It is persistent, systemic and quiet, detectable only through blood markers, which is exactly why it is hard to feel, hard to measure well, and easy to sell dubious remedies against.

The inflammatory clock

The most concrete recent advance is an attempt to measure it. Using the blood immune profiles of 1,001 people aged 8 to 96, researchers trained a deep-learning model to build an "inflammatory clock of ageing," called iAge, from patterns of age-related inflammation [s2]. The clock did what a useful biomarker should: it tracked with multimorbidity, with immunosenescence (the ageing of the immune system itself), with frailty and with cardiovascular ageing, and it was also associated with exceptional longevity in centenarians, who tended to have younger inflammatory ages than their calendar age [s2].

The single strongest contributor to a person's iAge was a chemokine called CXCL9, an immune signalling molecule [s2]. In follow-up laboratory work, ageing cells lining blood vessels showed loss of function and features of vascular stiffening that were reversed when CXCL9 was silenced, pointing to a specific, potentially targetable driver rather than a vague "inflammation" [s2]. That is the promise of inflammaging research: turning a fuzzy concept into named molecules you could, in principle, act on.

The gap between marker and outcome

Here is where honesty is required. Measuring inflammaging, and even identifying a molecule that drives part of it, is not the same as showing that lowering it extends life. The distinction is the same one that undoes most of the biological-age industry: a marker can move without the outcome following.

The best test of the underlying idea in humans comes not from ageing research but from cardiology. In the CANTOS trial, 10,061 people who had survived a heart attack and had raised inflammation, measured by high-sensitivity C-reactive protein, were given canakinumab, an antibody that blocks the inflammatory signal interleukin-1 beta, or placebo [s3]. The drug lowered cardiovascular events without changing cholesterol at all, the cleanest proof yet that inflammation itself, not just the lipids alongside it, is a cause of disease [s3]. That is a landmark result. But two caveats matter for anyone extrapolating to ageing: canakinumab also raised fatal infections, because damping the immune system has a price, and the outcome it improved was heart disease, not lifespan or healthspan [s3]. No trial has yet shown that an anti-inflammatory drug slows ageing across the board.

There is a further trap specific to the markers. The inflammation biomarker most people actually get measured, C-reactive protein, turns out to be a signpost rather than a cause; a large genetic analysis found it is not itself driving disease, a story told in full in our piece on inflammation as clinical concept versus marketing. So even the number in your blood test may not be the thing to target.

What it means for a reader

Inflammaging is a serious scientific idea with real supporting data, and it is also one of the most heavily marketed concepts in the wellness economy, attached to everything from supplements to "anti-inflammatory" diets to direct-to-consumer biological-age tests. The evidence supports the biology and does not yet support the products. What is established: inflammation rises with age, correlates with worse outcomes, and can be quantified in research settings [s1][s2]. What is not: that any consumer intervention lowers it in a way that changes how long or how well you live.

The iAge clock, like the epigenetic clocks whose reliability is still contested, is a research tool, not a validated consumer product, and a single reading tells an individual little. What to watch is whether trials that deliberately lower inflammation, using safer and more targeted approaches than a blunt immune-suppressing antibody, can show a benefit for ageing itself rather than for one disease. Until then, the accurate summary is that inflammaging is real, measurable, and not yet something you can buy your way out of.